RxElite, Inc. is a specialty pharmaceutical company that develops and markets generic prescription drug products in specialty generic markets. The company is headquartered in Eagle, Idaho and currently employs 47 full-time employees. The company went IPO on 2007-07-23. RxElite's markets and pipeline products are in specialty markets. These markets include specialty products in the areas of anesthesia gases, sterile liquid dose products, which includes ophthalmic products, sterile inhalation respiratory products and injectable, drugs and active pharmaceutical ingredients (APIs). The firm's customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. In January 2008, RxElite acquired FineTech Laboratories, Ltd, which manufactures APIs in its facility in Haifa, Israel. In January 2009, RXElite announced the sale of all the issued and outstanding capital stock of RxElite Holdings Inc. (Holdings), its wholly owned United States subsidiary, to Piramal Healthcare Limited.
Follow-Up Questions
Quel est le ratio P/E de RXElite Inc (RXEI) ?
Le ratio P/E de RXElite Inc est de 0
Quelle est la performance du prix de l'action RXEI ?
Le prix actuel de RXEI est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de RXElite Inc ?
RXElite Inc appartient à l'industrie N/A et le secteur est N/A
Quelle est la capitalisation boursière de RXElite Inc ?
La capitalisation boursière actuelle de RXElite Inc est de $0
